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T he incidence of gynecologic cancer (GC) has increased in Japan,  with an estimated 30,964 
patients newly diagnosed in 2009 [1].  Diagnostic tech-
niques and treatment modalities have advanced,  lead-
ing to earlier detection,  improved disease management,  
and prolonged survival.  Such improvements have 
caused a surge in the numbers of surviving patients with 
secondary primary cancer (SPC),  posing an additional 
threat in terms of morbidity and mortality.
The criteria for diagnosing SPC are (i) each mass has 
definite malignant features; (ii) each mass can be sepa-
rated from other masses; and (iii) the possibility of 
metastasis can be excluded [2].  The time interval of SPC 
occurrence is usually defined as synchronous if less 
than 6 months or metachronous if more than 6 months.  
Several studies have shown that the prognosis for meta-
chronous SPC is better than that for synchronous SPC 
[3-5].
The Surveillance Epidemiology and End Results 
(SEER) program reported that SPC accounts for 7% of 
cervical cancer (CC) patients,  11% of endometrial can-
cer (EM) patients,  and 5% of ovarian cancer (OV) 
patients [6].  However,  SPC has not been identified as a 
prognostic factor in patients with GC.  The present 
study therefore aimed to evaluate the correlations 
between SPC and both the clinical factors and prognosis 
of GC patients.
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This study aimed to determine whether the risk conferred by gynecologic cancer (GC) as second primary cancer 
(SPC) differs from that associated with GC as first primary cancer (FPC).  We investigated the correlations 
between FPC/SPC and the characteristics and prognoses of 1,645 GC patients (701 with cervical cancer [CC],  
641 with endometrial cancer [EM],  and 303 with ovarian cancer [OV]).  The χ2 test and the Kaplan–Meier 
method were used to determine whether FPC/SPC and the characteristics and prognoses of GC patients.  Of the 
SPC patients,  26 (3.7%) had CC,  53 (8.3%) had EM,  and 31 (10.2%) had OV.  The most common previous can-
cer type in SPC of GC patients was breast cancer,  which was observed in 13 patients (50.0%) with CC,  23 
(43.4%) with EM,  and 16 (51.6%) with OV.  In all patients with CC,  EM,  and OV as SPC,  the stage was signifi-
cantly associated with recurrence.  There were no significant differences in the morbidity or mortality of CC,  
EM,  or OV patients between those with FPC and those with SPC.  The risk of SPC development in GC patients 
varied,  ranging from 3.5% (CC) to 10.3% (OV) of patients.
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Patients and Methods
This retrospective study reviewed the medical 
records of 1,645 GC patients (701 CC patients,  641 EM 
patients,  and 303 OV patients) who were treated at the 
Department of Obstetrics and Gynecology of Okayama 
University Hospital between April 2004 and June 2018.  
The study protocol was approved by the Institutional 
Review Board of Okayama University Hospital (1906-
021).  Informed consent was obtained from all patients.  
The patients were treated in accordance with the clinical 
guidelines of the Japan Society of Gynecologic Oncology.  
Treatment options for gynecologic cancer included sur-
gery,  radiotherapy,  and/or chemotherapy,  depending 
on tumor stage and additional risk factors.
All patients underwent a review of their medical 
history,  staging,  histology,  physical examination,  fam-
ily histology,  and lifestyle (smoking and alcohol intake).  
Patient age was estimated based on the date of initial 
histologic diagnosis of cancer.  Height and weight were 
measured upon hospital entry before any therapeutic 
treatment for gynecologic cancer.  Body mass index 
(BMI) was defined according to the World Health 
Organization (WHO,  2015),  and used to classify 
patients as underweight (< 18.4 kg/m2),  normal weight 
(18.5-24.9 kg/m2),  overweight (25-29.9 kg/m2),  or 
obese (≥ 30.0 kg/m2).  SPC was defined as two or more 
primary cancers occurring in an individual that were 
not an extension,  recurrence,  or metastasis.
Statistical analysis. Data were analyzed using the 
χ2 and Mann–Whitney U-tests for multiple compari-
sons,  and by one-factor analysis of variance followed by 
Fisher’s protected least significant difference test for all 
pairwise comparisons.  Morbidity and mortality curves 
were calculated by the Kaplan–Meier method,  and dif-
ferences between the curves were examined using the 
log-rank test.  Analyses were performed using SPSS 
software version 20.0 (SPSS Inc.,  Chicago,  IL,  USA) 
with a significance level of 0.05.
Results
Table 1 lists the baseline characteristics (age,  stage,  
histology,  BMI,  and information regarding first-degree 
110 Ogawa et al. Acta Med.  Okayama　Vol.  74,  No.  2
Table 1　 Patient and tumor characteristics
CC EM OV
Numbers (%) Numbers (%) Numbers (%)
Age (year)
＜50 280 40 123 19.3 80 26.4
50-59 143 20.4 211 32.9 87 28.7
60-69 139 19.8 175 27.3 88 29
≥70 139 19.8 131 20.5 48 15.9
Stage
I 291 41.5 435 67.9 128 42.3
II 159 22.7 51 8 13 4.3
III 186 26.5 95 14.8 106 35
IV 65 9.3 60 9.3 56 18.4
Histology
CC; SCC,  EM; Low type,  OV; Serous Ca 526 75 419 65.4 120 4
CC; Non- SCC,  EM; High type,  OV; Non-serous Ca 175 25 222 34.6 183 96
BMI
＜18.5 104 14.6 42 6.7 19 6.3
18.5-24.9 436 62.2 346 54 229 75.6
25.0-29.9 128 18.5 141 22 44 14.5
≥30.0 33 4.7 111 17.3 11 3.6
First-degree relative with cancer
Negative 506 72.2 465 72.5 212 70
Positive 195 27.8 176 27.5 91 30
Smoking
Negative 538 76.7 606 94.5 284 93.7
Positive 163 23.3 35 5.5 19 6.3
Alcohol
Negative 619 88.3 607 94.7 284 93.7
Positive 82 11.7 34 5.3 19 6.3
Primary cancer
First primary cancer 675 96.3 588 91.7 272 89.8
Second primary cancer 26 3.7 53 8.3 31 10.2
CC,  cervical cancer; EM,  endometrial cancer; OV,  ovarian cancer; BMI,  body mass index; SCC,  squamous cell carcinoma; Ca,  cancer.
relatives with cancer,  smoking,  and alcohol intake) of 
the CC,  EM,  and OV patients.
Among the GC patients,  1,535 (93.3%) had first pri-
mary cancer (FPC) and 110 (6.7%) had SPC.  Of the 
SPC patients,  26 had CC (3.7%),  53 had EM (8.3%),  
and 31 had OV (10.2%).  Correlations between each 
type of primary cancer (FPC or SPC) and clinical char-
acteristics in GC (CC [n = 701],  EM [n = 641],  OV 
[n = 303]) patients were assessed.  Patients with CC as 
SPC were significantly more likely to be elderly or non-
smokers than those with CC as FPC (p < 0.001 or 
p = 0.004,  respectively).  Family history (first-degree 
relative with cancer) was more frequently observed in 
patients with EM as SPC than those with EM as FPC 
(p = 0.08).  However,  there were no significant relation-
ships between FPC and SPC for the other clinical char-
acteristics assessed (Table 2).
Table 3 shows the distributions of the parameters 
examined according to the clinical characteristics of 
SPC in CC,  EM,  and OV patients.  The most common 
previous cancer (history of first primary cancer) for SPC 
in GC patients was breast cancer.  Breast cancer 
accounted for 13 patients (50.0%) with CC,  23 (43.4%) 
with EM,  and 16 (51.6%) with OV.  We investigated the 
time interval of other sites of FPC to SPC in GC patients.  
One patient with CC (3.8%),  15 with EM (28.3%),  and 
8 with OC (25.8%) were diagnosed with synchronous 
SPC.  SPC in 11 patients with CC (42.3%),  30 patients 
with EM (54.7%),  and 19 patients with OC (61.3%) were 
occurred within 5 years from PFC (Table 3).
Patients underwent follow-up examinations approx-
imately every 1-2 months for the first 6 months,  every 3 
months for the next 2 years,  and every 6 months there-
after.  Median PFS and OS times for all patients in this 
study were 37.0 and 45.5 months with CC,  42.0 and 
48.0 months with EM,  and 23.0 and 38.0 months with 
OV,  respectively; the range for follow-up periods was 
1-166 months with CC,  1-166 months with EM,  and 
1-158 months with OV for both PFS and OS.  At the last 
follow-up point,  491,  512,  and 178 patients were alive 
with no evidence of disease; 138,  94,  and 74 patients 
had died of disease; and 72,  35,  and 51 patients were 
alive with disease for CC,  EM and OV,  respectively.
The correlations between clinical factors of SPC in 
CC,  EM,  or OV patients and progression-free survival 
(PFS) or overall survival (OS) were assessed in univari-
ate and multivariate analyses (Table 4).  In the univari-
ate analysis of PFS and OS,  stage was significantly 
associated with PFS (p = 0.005),  whereas stage was sig-
nificantly associated with OS (p = 0.025) in patients with 
CC as SPC.  In the univariate analysis of PFS and OS,  
age (p = 0.026),  time interval (p = 0.026),  histology 
(p = 0.017),  and stage (p = 0.036) were significantly asso-
ciated with PFS,  whereas age was significantly associ-
ated with OS (p = 0.033) in patients with EM as SPC.  In 
the univariate analysis of PFS and OS,  histology 
(p = 0.001) and stage (p < 0.001) were significantly asso-
ciated with PFS (p = 0.005),  whereas histology was sig-
nificantly associated with OS (p = 0.025) in patients with 
OV as SPC.  In the multivariate analysis,  age was sig-
nificantly associated with PFS in patients with EM as 
SPC.  Furthermore,  stage was significantly associated 
with PFS in patients with OV as SPC (p = 0.002).
Figure 1 shows the PFS and OS curves for the 1,645 
GC patients according to their FPC and SPC statuses.  
There were no significant differences between FPC and 
SPC for recurrence or survival in CC,  EM,  or OV 
patients.
Discussion
GC is one of the most common cancers in females 
worldwide,  but breakthroughs in diagnostic and thera-
peutic technologies have prolonged survival.  According 
to some studies,  as cancer survival rates have increased,  
the incidence of SPC has also gradually increased; this 
phenomenon appears to be due to a combination of 
genetic backgrounds and environmental effects [7-9].  
This is the first study to attempt to determine whether 
SPC is related to poor prognosis in GC patients.  In the 
present study,  we investigated the frequency of SPC in 
patients with CC,  EM,  and OV.  SPC was observed in 
3.7% of CC patients,  8.3% of EM patients,  and 10.2% 
of OV patients.  Breast cancer was the most common 
previous cancer in patients with GC as SPC,  account-
ing for approximately 50% of cases.  We investigated the 
time interval from previous cancer to SPC in GC 
patients; 3.8% of CC patients,  28.3% of EM patients,  
and 25. 8% of OC patients were diagnosed with syn-
chronous SPC.  In this study,  the recurrence and sur-
vival of patients exhibiting synchronous SPC were not 
significantly worse than those of patients with meta-
chronous SPC.
It has been reported that the incidence of SPC 
increases with age [4, 10-12].  Increasing age is thought 
to increase the incidence of SPC due to the increased 
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Table 2　 Tumor characteristics of second primary cancer compared with first primary cancer with gynecologic cancers
CC EM OV
FPC
n＝675
SPC
n＝26
FPC
n＝588
SPC
n＝53
FPC
n＝272
SPC
n＝31
Numbers Numbers p-value Numbers Numbers p-value Numbers Numbers p-value
Age (years) ＜0.001＊ 0.138 0.579
＜70 549 13 472 38 231 24
≥70 126 13 116 15 41 7
Stage 0.897 0.784 0.327
Early (Stage I-II) 433 17 445 41 124 17
Advance (Stage III-IV) 242 9 143 12 148 14
Histology 0.814 0.846 0.504
CC; SCC,  EM; Low type,  OV; Non-Serous Ca 507 19 385 34 106 14
CC; Non- SCC,  EM; High type,  OV; Serous Ca 168 7 203 19 166 17
BMI 0.248 0.409 0.375
＜30.0 642 26 484 46 263 29
≥30.0 33 0 104 7 9 2
First-degree relative with cancer 0.582 0.08 0.587
Negative 486 20 432 33 189 23
Positive 189 6 156 20 83 8
Smoking 0.004＊ 0.434 0.128
Negative 512 26 556 50 253 31
Positive 163 0 32 3 19 0
Alcohol 0.517 0.903 0.408
Negative 595 24 557 50 256 28
Positive 80 2 31 3 16 3
CC,  cervical cancer; EM,  endometrial cancer; OV,  ovarian cancer; BMI,  body mass index; FPC,  first primary cancer; SPC,  second primary can-
cer; SCC,  squamous cell carcinoma; Ca,  cancer.
＊p＜0.05
Table 3　 Tumor characteristics of second primary cancer with gynecologic cancers
CC EM OV
Numbers (%) Numbers (%) Numbers (%)
Second primary cancer
Double 25 96.2 51 96.2 30 96.8
Triple 1 3.8 2 3.8 1 3.2
First primary cancer
Breast cancer 13 50 23 43.4 16 51.6
Thyroid cancer 3 11.5 4 7.5 4 12.9
Colon cancer 5 19.2 6 11.3 4 12.9
Stomach cancer 2 7.7 4 7.5 1 3.2
Liver & Gallbladder cancer 0 0 3 5.7 0 0
Lung cancer 1 3.8 2 3.8 0 0
Cervical cancer - - 2 3.8 0 0
Ovarian cancer 0 0 6 11.3 - -
Endometrial cancer 0 0 - - 6 19.4
Hematologic marignanacy 0 0 2 3.8 0 0
Kidney cancer 1 3.8 2 3.8 1 3.2
Esophageal cancer 1 3.8 0 0 0 0
Other 1 3.8 1 1.9 0 0
Time Interval (years)
＜－0.5 year 1 3.8 15 28.3 8 25.8
－1＜ to ≤－0.5 year 2 7.7 2 3.8 1 3.2
－3＜ to ≤－1 year 4 15.4 5 9.4 2 6.5
－5＜ to ≤－3 year 4 15.4 7 13.2 8 25.8
－10＜ to≤－5 year 5 19.2 9 17 4 12.9
≥－10 year 10 38.5 15 28.3 8 25.8
CC,  cervical cancer; EM,  endometrial cancer; OV,  ovarian cancer.
cumulative exposure to various envi-
ronmental factors and to the 
increased risk of genetic mutations.  
Furthermore,  Yoshimoto et al.  
reported that family history is a factor 
that increases the incidence of SPC 
[13].  In this study,  we investigated 
age and family history in patients with 
CC,  EM,  and OV as SPC.  Patients 
with CC as SPC were significantly 
more likely to be elderly.  And,  family 
history tended to be more prevalent in 
patients with EM as SPC.  This study 
investigated PFS and OS in patients 
with CC,  EM,  and OV as SPC.  In all 
patients with GC (CC,  EM,  and OV) 
as SPC,  stage was significantly associ-
ated with PFS.  Only in patients with 
CC as SPC was stage significantly 
associated with OS.  Moreover,  multi-
variate analysis of our study popula-
tion showed that stage was inde-
pendently correlated with shorter PFS 
in patients with OV as SPC.  
Therefore,  stage may be useful in pro-
jecting prognostic factors for patients 
with GC as SPC.
SPC is an important prognostic 
factor in breast cancer [14].  In this 
study,  we also compared the progno-
ses of FPC and SPC in GC patients.  
There were no significant differences 
in the morbidity or mortality of CC,  
EM,  or OV patients between those 
with FPC and those with SPC.  We 
suggest that SPC was not a significant 
prognostic factor in GC patients.
We acknowledge that our study has 
some limitations.  The number of 
patients was relatively small,  and the 
examination was performed at a single 
facility.  Further prospective studies 
with more patients are needed to pro-
vide more definitive data to help clar-
ify the appropriate treatment for 
patients with GC as SPC.
In conclusion,  SPC accounted for 
3.7% of CC,  8.3% of EM,  and 10.2% 
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.
of OV in our subject group.  There were no significant 
differences in the morbidity or mortality of CC,  EM,  or 
OV patients between those with FPC and those with 
SPC.  Further,  it is important to establish an appropri-
ate treatment for patients with GC as SPC.
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Fig. 1　 Kaplan‒Meier curves for progression-free survival (PFS) or overall survival (OS) according to first primary cancer (FPC) and sec-
ond primary cancer (SPC) in CC,  EM,  and OV patients.
